
Trial monitors recommend Elevidys studies continue; Novartis kidney drug approved
Today, a brief rundown of news involving Sarepta Therapeutics, Novartis and Allakos, as well as updates from CSL Behring and Roche that you may have missed. A group of independent trial monitors on Friday recommended dosing continue in a trio of studies …